FLINT, Mich. – March 29, 2017 – The nation’s largest independent specialty pharmacy has been selected to dispense the limited-distribution drug OCREVUS™ (ocrelizumab) for primary progressive and relapsing multiple sclerosis.

Diplomat Pharmacy, Inc. (NYSE: DPLO) has been selected to the panel for the limited-distribution drug OCREVUS™ (ocrelizumab). OCREVUS was approved by the Food and Drug Administration for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

To learn more about Diplomat’s multiple sclerosis program, visit diplomat.is/areas-of-excellence/multiple-sclerosis/.

“We are excited to make this highly anticipated treatment option available to patients in need,” said Paul Urick, Diplomat’s president. “OCREVUS can reduce the burden of multiple sclerosis and give patients hope.”

Multiple sclerosis (MS) is a chronic disease that affects more than 400,000 people in the United States. MS is an unpredictable, often disabling disease of the central nervous system. It interrupts the flow of information within the brain and between the brain and the rest of the body. Symptoms can include numbness, tingling, blindness, paralysis, and cognitive difficulties. According to the National Multiple Sclerosis Society, most people with MS are diagnosed between ages 20 and 50, with at least twice as many women diagnosed as men.

RMS is the most common form of the disease. PPMS is a debilitating form marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. About one in 10 people with multiple sclerosis has the primary progressive form.

OCREVUS is being developed by Genentech and Roche. For full prescribing information, click here.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise. 

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

###

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is

Twitter